Results 191 to 200 of about 72,190 (302)

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

open access: yesCancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao   +12 more
wiley   +1 more source

Patient Dose Optimisation of Abdominopelvic Protocols During X‐Ray Imaging

open access: yesJournal of Medical Radiation Sciences, Volume 73, Issue 2, Page 156-163, June 2026.
This study evaluates organ doses in abdominopelvic radiography for both erect and supine positions, addressing dose optimisation concerns in Ghana. Using CalDose X and thermoluminescence dosimeters, organ doses and image quality were analysed, revealing significant dose reductions with optimised exposure parameters (70 kVp, 10 mAs, 110 cm FDD).
Emmanuel Ekem‐Ferguson   +3 more
wiley   +1 more source

Stabilised Hyaluronic Acid Gel Rectal Spacers in MRI‐Guided Brachytherapy for Gynaecological Cancers: A Prospective Feasibility Study

open access: yesJournal of Medical Radiation Sciences, Volume 73, Issue 2, Page 196-204, June 2026.
This prospective study investigated the feasibility of stabilised hyaluronic acid gel as a rectal spacer in gynaecological cancer brachytherapy. In twelve patients, the spacer was successfully inserted into the rectovaginal space without serious adverse events, had high visibility on MRI, increased the target‐to‐rectum distance compared with no spacer ...
Carminia Lapuz   +8 more
wiley   +1 more source

A survey of practice patterns for patient-specific quality assurance on behalf of the ESTRO dosimetry & quality assurance focus group. [PDF]

open access: yesPhys Imaging Radiat Oncol
Dufreneix S   +7 more
europepmc   +1 more source

Osteoradionecrosis After Modern Radiotherapy for Oral Cavity Cancer: Incidence and Risk Factors

open access: yesLaryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
This retrospective single‐institution review evaluated contemporary ORN rates in 172 patients with oral cavity squamous cell carcinoma treated exclusively with IMRT (2013–2022). Reported osteoradionecrosis (ORN) incidence after head and neck cancer IMRT is relatively low, however, the 3 year ORN incidence was 24% in this cohort and increased incidence ...
Alyssa Farley   +5 more
wiley   +1 more source

Experimental evaluation of an intraoperative-imaging based workflow for electron beam radiotherapy of pancreatic cancer using in situ dosimetry. [PDF]

open access: yesJ Appl Clin Med Phys
Iliaskou C   +8 more
europepmc   +1 more source

Global spotlight editorial: Advancing treatment planning to promote equity through AI and automation in clinical medical physics

open access: yes
Journal of Applied Clinical Medical Physics, Volume 27, Issue 6, June 2026.
Nataliya Kovalchuk   +4 more
wiley   +1 more source

The Tumor Immune Microenvironment in Endometrial Cancer: Composition, Molecular Subtypes, and Therapeutic Implications

open access: yesMedComm – Oncology, Volume 5, Issue 2, June 2026.
Endometrial cancer (EC), a major gynecologic malignancy and a representative “cold tumor”, exhibits a tumor immune microenvironment (TIME) influenced by a broad range of cellular and molecular elements, immunosuppressive signals, and pathways of immune evasion.
Jingxuan Ye   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy